Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novo Nordisk's diabetes drug

Novo Nordisk has received approval from the US FDA for its type 2 diabetes treatment, Victoza (liraglutide)

Danish pharmaceutical company, Novo Nordisk has announced it has been granted marketing authorisation from the US Food and Drug Administration (FDA) for its type 2 diabetes treatment, Victoza (liraglutide).

Victoza is approved for use in addition to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

"The US approval of Victoza represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe." said Lars Rebien Sørensen, president and CEO.

He continued: "We are convinced that Victoza will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Novo Nordisk plans to introduce Victoza to the US market within the next few weeks.

26th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics